2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies

por Vollmer, Jannik, Belley, Adam, Velicitat, Patrick, Machacek, Matthias
Publicado 2023

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021

por Belley, Adam, Kothari, Nimmi, Monti, Federica, Hawser, Stephen
Publicado 2023

637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Ur...

por Kaye, Keith S, Belley, Adam, Barth, Philip, Lahlou, Omar, Velicitat, Patrick
Publicado 2021

LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by...

por Belley, Adam, Barth, Philip, Kashyap, Shikhar, Lahlou, Omar, Motta, Paola, Knechtle, Philipp, Velicitat, Patrick
Publicado 2020

Strain-Specific Differences in the Genetic Control of Two Closely Related Mycobacteria

por Di Pietrantonio, Tania, Hernandez, Carmen, Girard, Manon, Verville, Annie, Orlova, Marianna, Belley, Adam, Behr, Marcel A., Loredo-Osti, J. Concepción, Schurr, Erwin
Publicado 2010